Advertisement
Search for

Volume 137, Issue 4, Pages 1238-1249 (October 2009)


View previous. 24 of 70 View next.

Additional Online Content AvailableBiology and Treatment of Eosinophilic Esophagitis

Marc E. RothenbergCorresponding Author Informationemail address

Received 26 May 2009; accepted 1 July 2009. published online 13 July 2009.

Eosinophilic esophagitis is a recently recognized but expanding disorder characterized by antigen-driven eosinophil accumulation in the esophagus. Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are distinct in their histopathology, gene expression signature, response to therapy, hereditary risk, and association with allergies. The pathogenesis of eosinophilic esophagitis involves environmental and genetic factors, particularly food antigens and expression level of the eosinophil chemoattractant eotaxin-3, respectively. Analyses of gene expression signatures and animal models have indicated the importance of adaptive T-cell immunity that involves interleukin-5 and interleukin-13–induced esophageal epithelial cell responses. Symptoms, dysregulation of esophageal gene expression, and pathology are largely reversible following reduced exposure to specific food antigens as well as anti-inflammatory therapy, but chronic treatment is necessary to prevent relapse. Therefore, eosinophilic esophagitis is a disease with unique features that include chronic esophagitis, atopy, immune sensitization to oral antigens, reversibility, and familial association.

John P. Lynch and David C. Metz, Section Editors

Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio

Corresponding Author InformationReprint requests Address requests for reprints to: Marc E. Rothenberg, MD, PhD, Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, Ohio 45229. fax: (513) 636-3310

 Conflicts of interest The author discloses the following: Dr Rothenberg is a paid consultant for Centocor, Ception Therapeutics, Merck & Co, Novartis, and Nycomed.

 Funding Supported by National Institutes of Health grants R01 AI45898, R01 DK067255, U19 AI070235, R01 DK076893, R01 AI057803, and P30 DK078392; the Campaign Urging Research for Eosinophilic Disorders; the Food Allergy and Anaphylaxis Network; the Food Allergy Project; and the Buckeye Foundation.

PII: S0016-5085(09)01156-1

doi:10.1053/j.gastro.2009.07.007


View previous. 24 of 70 View next.

Advertisement